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A B S T R A C T   
The purpose of this study was to investigate the role of piceatannol (PT) in statin (rosuvastatin and simvastatin) 
resistance and tolerance and its association with PCSK9 expression via its p300 inhibitory (p300i) activity. An in 
vitro study was performed using HepG2 cells that were exposed to statins (rosuvastatin or simvastatin) with or 
without PT in delipidated serum (DLPS) medium. In the statin exposed conditions, PCSK9 expression was 
reduced following PT treatment when compared to HepG2 cells w/o PT treatment. Furthermore, no significant 
difference was observed in the expression of the transcription factors SREBP2 and HNF1α, which regulate PCSK9 
expression. This resulted in low density lipoprotein receptor (LDLR) stabilization and reduced cellular cholesterol 
levels. This indicates that PT epigenetically controls statin-induced PCSK9 expression. Interestingly, PT attenu-
ated p300 histone acetyltransferase (HAT) activity. Moreover, simulation of PT-p300 binding suggested that PT 
inhibits p300 as PT could be docked in the p300 HAT domain. Furthermore, inhibition of p300 HAT activity 
using C-646, a selective p300 inhibitor, or through an siRNA system effectively reduced PCSK9 induction upon 
statin exposure in HepG2 cells. The chromatin immunoprecipitation (ChIP) assays revealed that PT blocked the 
recruitment of p300 to the PCSK9 promoter region. In summary, PT attenuated statin-induced PCSK9 expression 
by inhibiting p300 HAT activity. Finally, co-administration of simvastatin and PT for 10 weeks further reduced 
plasma low-density lipoprotein-cholesterol (LDL-C) levels and stabilized the hepatic LDLR protein level 
compared with those resulting from single treatment of simvastatin in a high-fat diet-induced hypercholester-
olemia mouse model. Our findings indicate that PT is a new nutraceutical candidate to reduce the statin resis-
tance and tolerance that occurs in patients with hypercholesterolemia.   
1. Introduction 
Cholesterol is an essential lipid that plays crucial roles in mammalian 
cells, such as structural integrity, stability, and cellular organization [1, 
2]. Conventionally, the cellular level of cholesterol is tightly regulated to 
maintain homeostasis, and its imbalance can be triggered by a 
combination of polygenic predisposition and nutritional factors to result 
in hypercholesterolemia [3]. Hypercholesterolemia is defined as the 
presence of abnormally high levels of cholesterol in the blood and is 
typically considered to be a secondary hyperlipidemia related to various 
disorders, such as type 2 diabetes (T2D) [4] and obesity [5]. Notably, 
elevated levels of low-density lipoprotein cholesterol (LDL-C) are known 
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to be related with the development of atherosclerotic cardiovascular 
disease [6]. 
Statins, which are a primary therapeutic intervention for hypercho-
lesterolemia, are a group of drugs that inhibit 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase (HMGCR). HMGCR is a core 
enzyme in the rate-limiting step of cholesterol synthesis that catalyzes 
the conversion of HMG-CoA to mevalonate [7,8]. Although statins have 
been one of the predominantly prescribed class of drugs to lower LDL-C 
levels in blood, they have the potential for adverse effects, as with other 
medications, due to the intermediates produced during the pharmaco-
logical processes [9–12]. As such, the biological influences of statins 
broaden even beyond the direct pathway implicated in mevalonate 
production, to include ripple effects by modifying the functions of other 
factors not directly involved in statin pharmacology [10]. The 
non-mevalonate effects of statins are represented by the increase in 
proprotein convertase subtilisin/kexin type-9 (PCSK9) [13], which 
subsequently increases circulating LDL-C levels by accelerating LDL 
receptor (LDLR) degradation [14]. 
PCSK9 was first identified as an essential regulator of LDL-C in 2003 
[15,16]. PCSK9 is synthesized predominantly in the liver and is secreted 
into blood with the signal peptide at the N-terminal removed [17]. 
Secreted PCSK9 binds to cell-surface LDLR and the complex is inter-
nalized and then targeted to the lysosome for degradation [18]. Thus, 
the simultaneous prescription of a PCSK9 inhibitor with statins has been 
considered as an effective method to overcome the adverse effect and 
resistance of statins. Evolocumab and alirocumab are human mono-
clonal antibodies that function as antagonistic PCSK9 inhibitors by 
binding to PCSK9 and are approved by the US Food and Drug Admin-
istration for the treatment of primary hyperlipidemia [19], either alone 
or in combination with other lipid-lowering therapies, such as statins 
and ezetimibe, a cholesterol absorption inhibitor [20]. Additionally, 
nutraceuticals, which use functional foods or dietary supplements with 
health benefits, have been considered to be effective additions or 
armamentarium to inhibit PCSK9 expression or activity given their 
economic advantages and the safety of their use [21]. Mechanistically, 
many studies have demonstrated that nutraceuticals tend to exert their 
PCSK9 inhibitory effect in a similar manner. Berberine enhances LDLR 
mRNA expression, resulting in increased LDL-C uptake [22], or sup-
presses PCSK9 expression at the transcriptional level by impeding the 
recruitment of HNF1α to the promoter region of the gene [23]. Curcu-
min also inhibits PCSK9 through the same mechanism as berberine [24]. 
Additionally, a growing body of evidence indicates that cholesterol 
homeostasis is controlled by epigenetic mechanisms, such as histone 
acetylation and DNA methylation, beyond the traditional regulatory 
schemes [25–27]. However, to the best of our knowledge, few studies 
have suggested or tested the capacity of nutraceuticals to reduce the 
statin-induced PCSK9 increase. Furthermore, no epigenetic regulatory 
mechanism has been identified to overcome the statin resistance and 
tolerance caused by reduced PCSK9 expression. This is especially true 
when considering the involvement of nutraceuticals in that mechanism. 
During an ongoing screen to identify phytochemical compounds with 
PCSK9 inhibitory activity and anti-histone acetyltransferase (HAT) ac-
tivity, we identified piceatannol (PT, trans -3,4,3′,5′-tetrahydrox-
ystilbene or 3,3′,4,5′-tetrahydroxy-trans-stilbene) as a novel PCSK9 
inhibitor (PCSK9i) and HAT inhibitor (HATi). PT is a naturally occurring 
phenolic compound found in various vegetables and fruits, such as 
grapes, peanuts, and berries [28]. PT, which has a similar structure to 
resveratrol, is more metabolically stable and has improved bioavail-
ability compared to resveratrol [29]. For this reason, many studies have 
demonstrated the role of PT in treating cancers, cardiovascular disease 
(CVD), and other chronic diseases; however, literature regarding PT’s 
beneficial effect in hypercholesterolemia is limited [28,30–32]. 
In the present study, we investigated the potential of PT as a new 
PCSK9i and revealed that PT effectively epigenetically reduced statin- 
induced PCSK9 expression through its anti-HAT activity. PT amelio-
rated the statin-induced PCSK9 expression in HepG2 cells. In addition, 
statin-induced PCSK9 expression was positively regulated by p300 HAT, 
and PT showed an inhibitory effect on p300 HAT activity. Moreover, PT 
blocked the recruitment of p300 to the PCSK9 promoter region. In a 
high-fat diet (HFD)-induced hypercholesterolemia mouse model, co- 
administration of simvastatin and PT further reduced plasma LDL-C 
and stabilized hepatic LDLR levels. 
2. Materials and methods 
2.1. Cell culture and reagents 
HepG2 cells (HB-8065) were purchased from the American Type 
Culture Collection (Manassas, VA, USA). The cells were cultured with 
high glucose Dulbecco’s modified Eagle’s medium (DMEM; Corning 
Inc., Corning, NY, USA) supplemented with 10 % fetal bovine serum 
(FBS) and 1% antibiotics (Welgene, Daegu, Korea) in a humidified at-
mosphere of 5% CO2 at 37 ◦C. After reaching ≈50 % confluence (day 0), 
the medium was changed to either DMEM supplemented with FBS or 
delipidated serum (DLPS) (day 1) that was prepared as previously 
described [33], and next day, the medium was changed to either FBS or 
DLPS supplemented DMEM with piceatannol (ChemFaces, Wuhan, 
China) alone or in combination with rosuvastatin or simvastatin (day 2). 
2.2. Statin treatment 
Either rosuvastatin or simvastatin was treated the HepG2 cells in 
delipidated conditions. HepG2 cells were seeded (day 0), and on day 1, 
the medium was changed to DMEM supplemented with either FBS or 
DLPS. On day 2, cells were exposed to a statin mixture (statins +50 μM 
mevalonate) with the replacement of DLPS supplemented media. After 
additional incubation for 18 h (day 3), the cells were harvested and used 
for experiments. 
2.3. Quantitative real-time RT-PCR 
1 × 106 cells were seeded in a 6-well plate and reaching ≈50 % 
confluence, the medium was changed to either DMEM supplemented 
with FBS or DLPS, and then next day, cells were treated with PT alone or 
in combination with statins as the indicated concentrations with 
replacement of the medium. After 18 h incubation, total RNA was 
extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and 
cDNA were synthesized using. qRT-PCR was performed with SYBR 
Green PCR master mix (Thermo Fisher Scientific, Waltham, MA, USA) 
using an I Cycler iQ system (Bio-Rad, Herculus, CA, USA). All reactions 
were carried out in triplicate using the primers listed in Supplemental 
Table 1. The relative mRNA expression levels were normalized to those 
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, and 
calculated using the comparative quantification method. 
2.4. Western blotting 
Following the cell treatment under the same conditions as used for 
qRT-PCR, cells were harvested, lysed using lysis buffer (Cell signaling 
Technology, Danvers, MA, USA) containing protease and phosphatase 
inhibitors (Roche, Basel, Switzerland), and incubated on ice for 30 min. 
The lysates were centrifuged at 20,000 × g for 20 min at 4 ◦C. The 
extracted proteins were separated on SDS-PAGE and transferred to 
nitrocellulose membranes. The membranes were blocked in 5% (w/v) 
non-fat Difco™ skim milk solution in 1 × PBS containing 0.05 % Tween- 
20 (PBST) for 1 h. The membranes were incubated with the indicated 
primary antibodies at 4 ◦C for overnight. All antibodies used in this 
study were at listed in Supplemental Table 2. Following the incubation 
with the primary antibodies, the membranes were washed with 1 ×
PBST, incubated with either the secondary anti-mouse or anti-rabbit 
horseradish peroxidase-conjugated antibody (Thermo Scientific, Tock-
ford, IL, USA) for 1 h, and visualized using the FUSION-SOLO6s imaging 
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system (Vilber Lourmat, ZAC de Lamirault, France) with an enhanced 
chemiluminescence detection reagent (Thermo Scientific). 
2.5. PCSK9 measurement 
After 70~80 % confluence, HepG2 cells were seeded in a 6-well plate 
with fresh DMEM (D0). Following incubation for 24 h, the media was 
changed to either DMEM supplemented with FBS or with delipidated 
serum (D1). After additional 24 h, the media was then changed to DMEM 
supplemented with either FBS or DLPS in the presence of PT (D2), fol-
lowed by incubation for additional 18 h (D3). The media was collected 
to evaluate extracellular PCSK9 protein level using a commercially- 
available ELISA kit (STA385; Cell Biolabs Inc., San Diego, CA, USA). 
In brief, samples and standards were added in 96-well plate pre-coated 
with antibody against PCSK9, and incubated for 3 h at 37 ◦C. After 
washing with wash buffer, the plate was incubated with horseradish 
peroxidase-conjugated secondary antibody for 1 h. Following additional 
washing, the plate was incubated with substrate solution for enzymatic 
reaction. The reaction was stopped by adding a stop solution, and the 
plate was read at 45 nm in a microspectrometer (Molecular Devices, 
Sunnyvale, CA, USA). PCSK9 was normalized to total protein contained 
in the media, which was measured using Bradford assay (Bio-Rad Lab-
oratories; Hercules, CA, USA). 
2.6. LDLR protein stability 
HepG2 cells were cultured as described above, and seeded in 6-well 
plate (D0). HepG2 cells were then incubated with fresh DMEM supple-
mented with DLPS (D1), followed by a treatment with either bafilomy-
cin A1 (BA1; B1739; Sigma-Aldrich) at 0 or 50 nM or PT at 0 or 40 μM 
(D2). After 24 h incubation (D3), the cells were washed with cold PBS, 
harvested, and centrifuged (1200 rpm, 3 min). 
2.7. Filipin staining assay 
HepG2 cells were cultured as described above, and seeded at 3 × 104 
cells/well in a 96-well plate (day 0). The medium was changed to DMEM 
supplemented with DLPS (day 1). Next day, the cells were exposed to a 
statin mixture (statins +50 μM mevalonate) with the replacement of 
DLPS supplemented media (day 2). After additional incubation for 18 h, 
the cells were washed with PBS for 3 times and then fixed with 3.7 % 
paraformaldehyde for 1 h at room temperature. The cells were rinsed 
with PBS for 3 times, followed by incubation with 100 μL of 1.5 mg 
glycine/mL in PBS for 10 min at room temperature to remove the re-
sidual paraformaldehyde. Filipin staining was conducted for 2 h at room 
temperature using 50 μg/mL of filipin solution in 10 % FBS solution in 
PBS. After completion of filipin staining, the cells were rinsed with PBS 
for 3 times, and fluorescence intensity was measured at 360/480 nm 
(exciation / emission) using SpectraMax M2 microplate reader (Molec-
ular Devices, Sunnyvale, CA, USA). 
2.8. siRNA transfection 
The siRNA sets were obtained from Genolution (Seoul, Korea): p300 
siRNA (sip300), sense 5′− CCUCGUGCCGUUCCAUCAGGUAGUU-3′, 
antisense 5′-CUACCUGAUGGAACGGCACGAGGUU -3′. 50 pmol of a 
non-specific siRNA (NC) or the sip300 was transiently transfected using 
Lipofectamine RNAiMax system into the cells according to the manu-
facturer’s guide. 
2.9. Histone acetyltransferase activity measurement 
For HAT assays based on cell free condition, either HeLa nuclear 
extract or p300 recombinant enzyme (BioVision Biotehnology, Milpitas, 
CA, USA) was used as the HAT enzyme source. HAT activities were 
assessed using a commercially available kit according to the 
manufacturer’s instrument (BioVision Biotechnology). IC50 values were 
calculated using Prism 7 software (Version 7.0.4; GraphPad Software 
Inc., CA, USA). To investigate the inhibitory effect of PA in the cell, 
cytosol and nuclear were respectively fractionized with Nuclear 
Extraction Kit (Abcam, Cambridge, UK) in accordance with the manu-
facturer’s protocol and each nuclear faction was used for the HAT 
assays. 
2.10. Animal experiments 
Male C57/BL6J mice (12-week-old) were purchased from Central 
Lab Animal Inc. (Seoul, Korea) and housed in a light-controlled room 
kept at a temperature of 23 ± 3 ◦C and a relative humidity of 50 ± 5% 
with free access to water and a diet. The protocol for the care and use of 
animals was approved by the Institutional Care and Use Committee at 
Korea Food Research Institute (#KFRI-M-17,010). After 1-week accli-
mation, 24 mice were fed with a high fat diet (HFD, Research Diet Inc. 
New Brunswick, NJ, USA) for 16 weeks. Mice were then randomly 
divided into 3 groups as follow: 1) HFD group (n = 8), 2) HFD with 
simvastatin (20 mg/kg body weight, n = 8), and 3) HFD with simva-
statin (20 mg/kg BW) and piceatannol (40 mg/kg body weight). Intake 
dosage and preparation method for simvastatin was determined as 
described previously with minor modification [36,34,35]. Simvastatin 
and piceatannol were provided by oral gavage, and PBS with 3.3 % 
ethanol and 5% 0.1 N NaOH, which together adjusted to pH 7, was used 
as a vehicle. Body weight was monitored every week. After 10-week 
treatment, mice were sacrificed after overnight fasting (10− 12 hours). 
Blood was collected from retro-orbital sinus. Serum was obtained by 
centrifugation (430 xg, 10 min) and analyzed (GC Lab Cell, Yongin, 
Korea). Liver was harvested, washed with saline solution, and stored at 
− 80 ◦C for further analysis. 
2.11. Hematoxylin and eosin staining 
The specimens fixed in 4% formalin, embedded in paraffin, and cut 
into 4–5 μm-thick sections, which were stained with hematoxylin and 
eosin (H&E). Lipid droplets were assessed by microscopic observation 
using an LEICA DM500 microscope (LEICA, Wetzlar, Germany), and 
captured by LEICA ICC50 HD (LEICA). 
2.12. Docking simulation 
A crystal structure of p300 HAT domain was retrieved from the 
Protein Data Bank (http://www.rsch.org/pdb/) (PDB ID: 4PZB). The 
structure contains an acetyl-CoA, and a Y1467 F mutation was intro-
duced near the acetyl groups of acetyl-CoA. The phenylalanine at res-
idue 1467 was mutated back into the tyrosine using the muatagenesis 
module in PyMol (The PyMOL Molecular Graphics System, 
Version2.2.2, Schrödinger, LLC.). The structure of piceatannol and C- 
646 were retrieved from PubChem, with CID of 667,639 and 1285941, 
respectively [37]. The structures were converted into MOL2 and PDBQT 
formats using the Open Babel Package (Version 2.4.1) [38] and Auto-
Dock Tools (Version 1.5.7) [39]. The ligand molecules were docked in 
the 30 Å cubic box placed near the acetyl-CoA binding site of the HAT 
domain using AutoDock Vina (Version 1.14.2, the Scripps Research 
Institute, La Jolla, CA, USA) [40]. The docking poses of the lowest 
docking scores were inspected and illustrated by using PyMol (The 
PyMOL Molecular Graphics Systems). 
2.13. Chromatin immunoprecipitation assay 
Cells (5 × 106) were seeded in 100-mm dishes and treated with PT in 
presence or absence of simvastatin at the indicated concentrations for 18 
h to reach approximately 70 % confluence (~2 × 108 cells). A chromatin 
immunoprecipitation (ChIP) assay was carried out by following a pre-
viously described method [41]. Briefly, cells were initially treated with 
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PBS containing 1% formaldehyde for 10 min, washed twice with cold 
PBS, and then incubated with 100 mM Tris (pH 9.4) and 10 mM DTT at 
30 ◦C for 15 min. The cells were then rinsed twice in PBS and resus-
pended in 600 μL of SolA [10 mM HEPES (pH 7.9), 0.5 % NP-40, 1.5 mM 
MgCl2, 10 mM KCl, and 0.5 mM DTT] by pipetting. After a short spin, the 
pellets were resuspended in SolB [20 mM HEPES (pH 7.9), 25 % glyc-
erol, 0.5 % NP-40, 0.42 M NaCl, 1.5 mM MgCl2 and 0.2 mM EDTA] 
containing protease inhibitors, followed by vigorous pipetting to extract 
nuclear proteins. After centrifugation at 13,000 rpm for 30 min, the 
nuclear pellets were resuspended in immunoprecipitation buffer [1% 
Triton X-100, 2 mM EDTA, 20 mM Tris− HCl (pH 8.0), 150 mM NaCl and 
protease inhibitors], and chromatin was broken by micrococcal nuclease 
digestion using a Pierce Agarose ChIP Kit (Thermo Fisher Scientific) into 
fragments of 0.5–1.0 kb average length. The ChIP assays were then 
preformed using the indicated antibodies essentially as described 
(Supplemental Table 2) but without SDS in all buffers. The primers used 
for ChIP assays are listed in Supplemental Table 1. All reactions were 
normalized relative to input activities and are presented as the mean ±
SD of three independent experiments. 
2.14. Statistical analysis 
Data were analyzed using either students’ t-test or one-way analysis 
of variance with Tukey’s multiple comparison test, and values were 
expressed at the mean ± SD. Statistical analysis was carried out using the 
SPSS software (Version 20; SPSS Inc., Chicago, IL, USA). Difference were 
considered statistically significant at p < 0.05. 
3. Results 
3.1. PT suppresses delipidation-induced intra-/extra-cellular PCSK9 
levels and stabilizes LDLR by downregulating SREBP2 and HNF1α 
transcription factors 
It is well established that LDLR and PCSK9 are the key factors that 
ultimately control steady-state serum LDL-C levels [42]. Thus, we hy-
pothesized that PT would lower LDLR and PCSK9 levels. To test this 
hypothesis, we measured the protein and mRNA expression levels of 
LDLR and PCSK9 following PT treatment using the DLPS system. First, 
we compared the effect of PT with resveratrol, which is known to inhibit 
PCSK9. As shown in supplementary Fig. S1, PCSK9 inhibition and LDLR 
Fig. 1. PT abrogated PCSK9 gene expression 
through inhibiting the transcription factors 
HNF1α and SREBP2, and stabilized LDLR 
through obstruction of lysosomal degradation. 
(A) PT decreased PCSK9 and increased LDLR 
expression levels. HepG2 cells were exposed to 
DLPS with or without PT at the indicated con-
centrations for 18 h. Total protein was extrac-
ted from the harvested cells and used for 
western blotting to detect the indicated pro-
teins. ###p < 0.001. (B) PT decreased LDLR 
and PCSK9 mRNA expression levels. HepG2 
cells were treated with PT at the indicated 
concentrations under the DLPS condition for 18 
h; mRNA expression of LDLR and PCSK9 was 
measured by qRT-PCR. The values presented 
are the means ± SD of three independent ex-
periments; ###p < 0.001. (C) PT reduced the 
PCSK9 protein level in medium. HepG2 cells 
were treated with PT at the indicated concen-
trations with DLPS. After 18 h, the medium was 
collected and used for measuring PCSK9 levels. 
(D) PT blocked the lysosomal degradation of 
LDLR. HepG2 cells were exposed to the DLPS 
condition with 40 μM PT or 10 μM BA1 alone or 
in combination for 24 h. The cells were har-
vested and total protein was extracted. LDLR 
expression was measured using western blot-
ting with a specific antibody (upper panel). 
Means with different superscript letters are 
significantly different (p < 0.05) (lower panel). 
(E) PT reduced SREBP2 and HNF1α mRNA 
expression levels. HepG2 cells were treated 
with PT at the indicated concentrations under 
the DLPS condition for 18 h. mRNA expression 
of SREBP2 and HNF1α was measured by qRT- 
PCR. The values presented are the means ±
SD of three independent experiments; ###p <
0.001.   
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stabilization were relatively higher following PT treatment than after 
resveratrol treatment. DLPS triggered the stabilization of LDLR and 
PCSK9. However, following PT treatment, LDLR expression levels were 
significantly increased in a dose dependent manner. In contrast, the 
stabilized PCSK9 levels in response to DLPS were destabilized upon PT 
treatment (Fig. 1A). To determine whether the changes in expression of 
these two proteins were due to changes in mRNA production, we 
examined the mRNA expression levels of LDLR and PCSK9 using 
qRT-PCR under the same conditions as western blotting. Interestingly, 
the transcription of PCSK9 was dramatically suppressed by PT treatment 
in a dose-dependent manner (Fig. 1B, right panel) while the transcrip-
tion of LDLR was unaffected by PT treatment (Fig. 1B, left panel). To 
determine whether the reduced levels PCSK9 in the cell also influenced 
PCSK9 levels in the blood, secreted-PCSK9 concentrations were detec-
ted. As shown in Fig. 2C, extracellular PCSK9 concentrations were 
markedly decreased following PT treatment, and PT treatment caused 
Fig. 2. PT induced PCSK9 reduction and LDLR stabilization regardless of the transcription factor, SREBP2 and HNF1α, under treatment with the DLPS-statin 
combination. (A, B) Statins increased PCSK9 and LDLR levels in a dose-dependent manner. HepG2 cells were treated with either rosuvastatin or simvastatin at 
the indicated concentrations for 18 h. RNA or total protein was extracted from the harvested cells, and PCSK9 or LDLR expression was measured using western 
blotting (A) or qRT-PCR (B). The values presented are the means ± SD of three independent experiments; *p < 0.05, **p < 0.01, and *** p < 0.001. (C) PT controlled 
the statins-induced PCSK9 increase, resulting in more stabilized LDLR. HepG2 cells were treated with either 0.2 μM rosuvastatin or 0.2 μM simvastatin in the presence 
or absence of PT at the indicated concentrations for 18 h. Total protein was extracted from the harvested cells and used for western blotting to determine LDLR and 
PCSK9 protein levels; #p < 0.05 and ###p < 0.001. (D) The statins-induced PCSK9 mRNA increase was reduced following PT treatment. PT was applied with either 
0.2 μM rosuvastatin or 0.2 μM simvastatin to HepG2 cells for 18 h. RNA was extracted, reverse-transcribed to cDNA, and then used in qPCR to measure PCSK9 mRNA 
levels. The values presented are the means ± SD of three independent experiments. ***p < 0.001 and #p < 0.05. (E) PT did not affect SREBP2 and HNF1α expression 
in the statin-exposed condition. HepG2 cells were exposed to 0.2 μM rosuvastatin or 0.2 μM simvastatin with or without PT for 18 h. RNA was extracted from the 
harvested cells, and SREBP2 and HNF1α expression levels were measured using qRT-PCR. The values presented are the means ± SD of three independent experi-
ments; **p < 0.01, ***p < 0.001, and #p < 0.05. (F) PT reduced free cholesterol in cells to a greater extent than statin. HepG2 cells were exposed to 0.2 μM 
rosuvastatin or 0.2 μM simvastatin with 40 μM PT for 24 h. To measure the amount of cholesterol in the plasma membrane, cells were stained with the fluorescent 
dye Filipin III, and the fluorescence intensity was measured using a fluorescence microplate reader. 
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similar changes in the protein and mRNA levels of PCSK9. To determine 
the mechanisms through which PT regulates LDLR and PCSK9, we hy-
pothesized that PT could affect LDLR stabilization by blocking its lyso-
somal degradation given the results presented in Fig. 1A and 1B. To the 
test our hypothesis, a lysosomal protease inhibitor, BA1, was used. As 
shown in D, LDLR expression was stabilized by PT treatment, although 
the stabilization was relatively lower than that caused by BA1 alone. 
However, LDLR was noticeably stabilized when a combination of BA1 
and PT was used. Based on previous results, changes in the intracellular 
or extracellular PCSK9 levels were mediated by the PT-mediated regu-
lation of PCSK9 mRNA expression. Thus, the mRNA expression of two 
transcription factors, SREBP2 and HNF1α, which are known to regulate 
transcription of PCSK9, were measured using qRT-PCR. As shown in 
Fig. 1E, the increase in SREBP2 and HNF1α mRNA levels in response to 
DLPS were significantly reduced upon PT treatment. Taken together, PT 
suppressed the intracellular or extracellular PCSK9 levels by down-
regulating the transcription factors SREBP2 and HNF1α, and stabilized 
LDLR expression levels by inhibiting lysosomal degradation. 
3.2. PT ameliorates statin resistance by reducing PCSK9 expression and 
stabilizing LDLR 
Although PT suppressed mRNA expression of HMGCR, a key enzyme 
for mevalonate biosynthesis, in the DLPS system (Supplementary 
Fig. S2), from the results obtained, we inferred that PT administered for 
hypercholesterolemia could overcome non-mevalonate side-effects of 
statins by suppressing PCSK9 and further stabilizing LDLR. To further 
explore this scenario, PT was administered with rosuvastatin or simva-
statin in the DLPS condition. Statins, rosuvastatin or simvastatin, upre-
gulated PCSK9 and LDLR protein and mRNA expression in the presence 
of mevalonate (Fig. 2A, B). Following treatment with a combination of 
each statin and PT, not only was LDLR clearly stabilized but PCSK9 was 
also degraded in a PT-concentration dependent manner (Fig. 2C), 
without regard to the inhibitory effect of PT on the mRNA expression of 
HMGCR and HMGCS2, which encode mevalonate synthesis enzymes 
(Supplementary Fig. S3). To determine if these results had the same 
underlying mechanism as that of the DLPS system (Fig. 1), PCSK9 mRNA 
expression was detected with the indicated conditions using qRT-PCR 
(Fig. 2D). Each statin induced PCSK9 mRNA expression, and this was 
significantly reduced upon PT treatment (Fig. 2D). Interestingly, 
following PT treatment, there was a noticeable difference in the regu-
lation of SREBP2 and HNF1α under statin treatment compared to DLPS 
treatment alone. As shown in Fig. 2E, a combination of PT and statins 
did not affect the regulation of SREBP2 and HNF1α. To determine 
whether the PT-derived intracellular actions do indeed lower the 
cholesterol, the classical filipin cholesterol staining was adapted. 
Intracellular cholesterol was increased by statin treatment and was 
conspicuously repressed following PT treatment (Fig. 2F) These results 
Fig. 3. PT inhibited histone acetyltransferase activity. (A) PT is a potential HAT inhibitor. A colorimetric assay using a cell-free system was conducted to measure 
HAT activity in the presence of PT at the indicated concentrations. The results are presented as the relative fold change to the control (NE alone) sample, which was 
incubated without PT (left panel). The IC50 value of PT for inhibition of HAT activity was calculated using Prism software (right panel). Means with different su-
perscript letters are significantly different (p < 0.05) (left panel). (B) HAT activity in nuclear extracts of HepG2 cells was also inhibited following PT treatment. The 
HAT activity was measured in NE from HepG2 cells. PT was treated to HepG2 cells for 24 h, and the nuclear fraction was obtained and then used as the enzyme source 
to measure HAT activity. Activity in each group is presented as a percentage relative to that in the control group. The values presented are the mean ± SD of three 
independent experiments. Means with different superscript letters are significantly different (p < 0.05) (left panel). To confirm the fraction, western blotting was 
carried out; HDAC1 and tubulin were used as nuclear and cytosol markers, respectively (right panel). 
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supported our hypothesis that PT may improve the statin-induced non- 
mevalonate effect by suppressing PCSK9 and stabilizing LDLR inde-
pendent of other transcription factors. 
3.3. PT is a potent novel histone acetyltransferase inhibitor 
Previously, we confirmed that the PT-mediated regulation of PCSK9 
under statin treatment conditions was independent of the transcription 
factors, SREBP2 and HNF1α. Therefore, we deduced that the control of 
the two genes was likely achieved by epigenetic mechanisms. To assess 
this, we initially measured histone acetyltransferase activity in a cell- 
free system following PT treatment at the indicated concentrations. In 
this system, HeLa cell nuclear extract (NE) was used as the source of HAT 
enzymes. As shown in Fig. 3A (left panel), PT significantly inhibited the 
global HAT activity with an IC50 value of 19.89 μM (right panel). To 
determine if HAT enzymes are truly implicated in the statin-induced 
non-mevalonate effect following PT treatment, we re-examined HAT 
activity in cells under the indicated conditions and measured total HAT 
activity in isolated nuclear fractions. In the DLPS and statin co-treated 
groups, HAT activity was significantly higher than in the DLPS-only 
treated group, and this increase in HAT activity was significantly 
inhibited by PT treatment (Fig. 3B, left panel). Western blotting 
confirmed successful cell fractionation (Fig. 3B, right panel). These re-
sults indicate that PT is a potent novel histone acetyltransferase inhibitor 
(HATi), and PT may be able to control statin-induced PCSK9 expression 
through this novel function. 
3.4. PT suppresses statin-induced PCSK9 expression by inhibiting p300 
Previous studies have demonstrated that p300, a representative HAT, 
is transcriptionally regulates LDLR and PCSK9 [43]. Thus, we investi-
gated whether PT modulates p300 activity. As shown in Fig. 4A, as ex-
pected, p300 activity was significantly inhibited by PT in a dose/time 
dependent manner. Next, we investigated the possibility for binding 
Fig. 4. PT suppressed statins-induced PCSK9 
expression through inhibition of p300 HAT ac-
tivity by docking in the p300 HAT domain. (A) 
PT showed a p300 acetyltranferase inhibitory 
effect. The P300 enzyme-specific anti-HAT ac-
tivity of PT was measured using a recombinant 
protein. A colorimetric assay using a cell-free 
system was conducted to measure p300 HAT 
enzyme activities in the presence of PT at the 
indicated concentrations. The results are pre-
sented as relative fold changes to a control 
sample, which was prepared without PT. The 
values presented are the means of three inde-
pendent experiments. (B) PT was expected to 
bind the p300 catalytic pocket at the HAT 
domain. The most likely PT-p300 docking is 
presented (left panel), and the docking site is 
expanded (right panel). The target protein 
(p300) is represented by a gray surface area and 
the ligands (PT or acetyl-CoA) are represented 
by sticks. When selecting the lowest energy 
ligand in the cluster, free energy (lowest energy 
+ (–kTlnN), k: Boltzman constant, T: Kelvin 
temperature, N: number of structures in each 
cluster) was used to account for the number of 
ligands in the population. (C) The inhibition of 
p300 activity reduced statins-triggered PCSK9 
induction. HepG2 cells were exposed to either 
rosuvastain or simvastatin with or without (w/ 
o) C-646, a p300-selective inhibitor for 18 h. 
RNA was extracted, and cDNA was synthesized 
and then used for qPCR. The values presented 
are the means ± SD of three independent ex-
periments; ##p < 0.01 and ###p < 0.001. (D) 
P300 knockdown using siRNA reduced statins- 
induced PCSK9 expression; 50 pmol p300 
siRNA was transiently transfected into HepG2 
cells, which were treated with statins the next 
day for 18 h. RNA was extracted, and cDNA was 
synthesized and then used for qPCR. The values 
presented are the means ± SD of three inde-
pendent experiments; ###p < 0.001 and ***p 
< 0.001.   
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between PT and p300 through a docking simulation. In the docking 
model, the two aromatic rings of PT were placed on the HAT domain of 
p300 surrounded by the hydrophobic residues I1395, Y1397, L1398, 
I1435, Y1446, L1463, and Y1467, where the β-mercaptoethylamine and 
pantothenate moieties of acetyl-CoA bind (Fig. 4B). The polar hydroxyl 
groups of PT were located at the ends of the channel that are exposed to 
solvent. Corresponding locations are occupied by the acetyl and phos-
phate groups of acetyl-CoA in its complex structures. The hydrophobic 
and hydrophilic pattern of PT moieties were matched to that of the p300 
HAT domain, and this was consistently observed in the top four docking 
structure (Supplementary Fig. S4). The data indicate that PT may control 
the activity of p300 by disturbing the binding of acetyl-CoA to the p300 
HAT domain. To establish the relationship between the PCSK9 mRNA 
expression and p300 activity, C-646, a specific p300/CBP inhibitor, and 
p300 siRNA were used. Cells were incubated with statins in the presence 
or absence of C-646 under DLPS-exposed conditions, and PCSK9 mRNA 
expression was measured. As shown in Fig. 4C, the increased mRNA 
expression of PCSK9 caused by statins was significantly reduced by 
inhibiting p300 with C-646. To confirm this, p300 was selectively 
knocked down using siRNA, and PCSK9 expression was measured. 
Remarkably, the statins (rosuvastatin and simvastatin) failed to increase 
PCSK9 expression upon p300 knockdown, and PCSK9 was expressed at a 
similar level to that of the PT-treated condition (Fig. 4D). Altogether, 
these data indicated that p300 is responsible for the statin-induced in-
crease in PCSK9 expression, and PT effectively blocks this by attenuating 
p300 activity by binding the p300 HAT domain (Fig. 5). 
3.5. PT abrogates p300 recruitment to the PCSK9 promoter region 
The p300-induced modulation of lysine acetylation on histones in 
promoter regions triggers conformational changes in DNA, influencing 
the transcriptional activity of genes [44]. To elucidate whether the 
changes in PCSK9 mRNA expression are regulated by recruitment of 
p300 to the PCSK9 promoter region, we performed chromatin immu-
noprecipitation (ChIP) assays. As shown in Fig. 6, simvastatin treatment 
enhanced p300 enrichment at the PCSK9 promoter region (-337 ~ -278 
bp), and this was effectively diminished upon treatment with 40 μM PT. 
Our findings indicate that PT may induce hypoacetylation of histones 
around the PCSK9 promoter region by reducing p300 binding in the 
region, which consequently affects PSCK9 mRNA expression. 
3.6. PT overcomes stain side effects in HFD-fed mice 
To confirm whether PT effectively attenuates the statin-induced 
PCSK9 increase and consequently stabilizes LDLR, as well as reduces 
the LDL-C level in blood, we conducted an in vivo experiment with an 
HFD mouse model. In brief, mice were fed an HFD for 16 weeks, and 
were then treated with either simvastatin alone or with the simvastatin- 
PT combination for 10 weeks. As shown in Fig. 6A and 6B, there were no 
significant differences in body weight, weight gain, and fat mass among 
the groups. However, the liver mass was effectively reduced in the 
treatment groups with either simvastatin alone or the simvastatin-PT 
combination compared with that of the control group (no treatment). 
Interestingly, the simvastatin-PT combination most strongly suppressed 
the LDL-C and total-C levels in the blood compared with the other two 
groups (Fig. 6C). No change in the triglyceride level was detected among 
groups (Fig. 6C, right panel), and there were also no differences in the 
toxicity indicators such as ALP, ALT, and AST among groups (Supple-
mentary Fig. S5). Finally, LDLR was expressed at the highest level in the 
simvastatin-PT combination group (Fig. 6D), which verified the in vitro 
effect that reducing the LDL-C level following PT administration was 
mediated through suppressing stain-induced LDLR degradation. Taken 
together, these results confirmed that PT reduced the LDL-C level by 
enhancing LDLR stabilization, suggesting that the side effects of statins 
can be overcome through PT administration to consequently improve 
the therapeutic efficacy of statin. 
4. Discussion 
It is well known that statins are the core HMG-CoA inhibitors used in 
pharmacological therapy to treat hypercholesterolemia [45]. Further-
more, they have been proven to be safe for use in reducing the occur-
rence of stroke, peripheral vascular disease, coronary disease, and LDL-C 
levels [46]. Despite the various benefits of statins, they occasionally 
cause resistance or intolerance in patients due to differences in protein 
expression across various target pathways that are unrelated to its 
pharmacokinetic mechanisms. These include alterations in HMG-CoA 
reductase, as well as in diverse factors implicated in cholesterol 
biosynthesis and the lipoprotein metabolic pathway [47]. PCSK9 is also 
known to be a major factor that induces the non-mevalonate effects that 
cause statin resistance and intolerance. Rashid et al. [48] reported that 
administration of statin to Pcsk9 knockout mice led to a substantial in-
crease in hepatic LDLR protein and reduction of plasma LDL-c levels. For 
this reason, PCSK9i, such as evolocumab, have been considered as novel 
medications for lowering LDL-C levels in patients who are unable to 
achieve normal levels of LDL-C with statins [49]. Our study suggested 
that PT could be a novel potent PCSK9i and elucidated its mechanism of 
action at the molecular level. 
Initially, we found PT to have powerful anti-lipogenic effects (Sup-
plementary Fig. S6) during an ongoing screening study using 3T3-L1 
preadipocytes to identify phytochemicals exhibiting anti-obesity ef-
fects. To confirm the efficacy of PT, we evaluated whether PT can 
improve various pathological phenomena implicated in obesity 
following ingestion of 0.025 % or 0.05 % PT for 12 weeks in a WD- 
induced obesity model (Supplementary Fig. S7). Consistent with previ-
ous reports [50,51], our data showed a decrease in weight gain, liver 
mass, retroperitoneal and epididymal fat mass, the reduction of the size 
of epididymal fat cells, and inhibition of lipid accumulation in hepato-
cytes. Sufficient evidence has been accumulated to support the claim 
Fig. 5. PT blocked simvastatin-induced p300 recruitment to the PCSK9 pro-
moter region. HepG2 cells were treated with 0.2 μM simvastatin in the presence 
or absence of PT at the indicated concentrations for 24 h, and ChIP assays were 
performed using the indicated antibodies. The precipitated samples were 
analyzed by qRT− PCR. The values presented are the means ± SD of three in-
dependent experiments. Means with different superscript letters are signifi-
cantly different (p < 0.05). 
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that PT helps overcome insulin resistance in high-fat diet-induced T2DM 
mice [52,53]. Therefore, in this study, we noted the PT-induced 
lowering of LDL-C given that the previously mentioned efficacy has 
already been identified. 
Following PT treatment in the DLPS-treated HepG2 model, we found 
that PT downregulated PCSK9 expression by downregulating the tran-
scription of the transcription factors SREBP2 and HNF1α, which are 
responsible for PCSK9 mRNA expression. In 2010, the strong induction 
of PCSK9 expression by SREBP2 and HNF1αwas reported [54]. This was 
further supported by additional reports that circulating PCSK9 and 
LDL-C levels were reduced by liver-specific knockdown of HNF1α [55] 
and that SREBP2 deletion in mouse hepatocytes led to the preferential 
inactivation of PCSK9 [56]. Many studies have identified that SREBP2 
controls LDLR expression to maintain cholesterol homeostasis [57,58]. 
As expected, LDLR mRNA expression was also decreased in a PT-treated 
group in a concentration dependent manner, similar to SREBP2 
expression. However, it is important to note that LDLR exhibited 
increased protein expression depending on the concentration of PT, 
unlike its mRNA expression, indicating that PT regulates LDLR at the 
post-translational level. In addition, our data, which showed dramatic 
LDLR stabilization following PT treatment with BA1, supported this 
notion. Based on these results, we inferred that PT-triggered LDLR 
expression could be regulated through the following two mechanisms: i) 
PT could directly stabilize LDLR at the post-translational level itself; ii) 
PT could indirectly stabilize LDLR by reducing PCSK9 expression. PCSK9 
binds to LDLR and makes it a target for lysosomal degradation in cells, 
which consequentially causes plasma clearance of LDL-C from the blood 
to fail [44,45]. A previous study showed that Pcsk9 knockout resulted in 
an increase in hepatic LDLR protein independent of its mRNA alteration, 
and improved plasma LDL clearance in mice [48]. Therefore, the inhi-
bition of either PCSK9 mRNA or protein expression, by monoclonal 
antibodies or small molecules, respectively, is a compromising strategy 
for hypercholesterolemia therapy [59]. Additionally, we cannot rule out 
the possibility of controlling the E3 ubiquitin ligase, IDOL (inducible 
Fig. 6. PT regulates HFD-mediated patholog-
ical features in obese mice. (A) Body weight 
changes, weight gain, and fasted body weight in 
mice fed the HFD alone, HFD feeding followed 
by simvastatin administration (20 mg/kg BW), 
or HFD feeding followed by combined simva-
statin (20 mg/kg BW) and PT (40 mg/kg BW) 
administration (n = 8/group). Mice were fed 
the HFD for 16 weeks, and then treated with 
either simvastatin or simvastatin + PT for an 
additional 10 weeks. Simvastatin or simvastatin 
+ PT did not affect body weight changes, 
weight gain, or final body weight in obese mice. 
(B) Masses of tissues (liver and fat) from mice 
fed the HFD alone, HFD with simvastatin (20 
mg/kg BW), or HFD with simvastatin (20 mg/ 
kg BW) and PT (40 mg/kg BW; n = 8/ group). 
Simvastatin and simvastatin + PT significantly 
attenuated the liver mass, but not fat mass, in 
obese mice compared to HFD-fed mice. (C) 
Blood lipid profile from mice fed the HFD alone, 
HFD with simvastatin (20 mg/kg BW), or HFD 
with simvastatin (20 mg/kg BW) and PT (40 
mg/kg BW; n = 8/group). Both simvastatin and 
simvastatin + PT significantly attenuated LDL 
cholesterol in obese mice (left panel), and sim-
vastatin + PT significantly reduced total 
cholesterol compared to HFD-only or 
simvastatin-treated obese mice (middle panel). 
The triglyceride (TG) level was not affected by 
diet, simvastatin, or PT. The values presented 
are the means ± SD;*p < 0.05, **p < 0.01, ***p 
< 0.001. (D) Hepatic LDLR levels in mice fed 
the HFD alone, HFD with simvastatin (20 mg/ 
kg BW), or HFD with simvastatin (20 mg/kg 
BW) and PT (40 mg/kg BW; n = 4/group). 
Simvastatin+PT significantly stabilized hepatic 
LDLR in obese mice. The LDLR protein levels in 
the mouse liver were immunoblotted by west-
ern blotting (left panel) and quantified by 
Image J software (right panel). The values 
presented are the means ± SEM (n = 4);***p <
0.001.   
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degrader of the LDLR), by PT. IDOL accelerates LDLR degradation 
through the ubiquitination of its C-terminus [60]. Thus, the regulation of 
IDOL by PT or obstruction of IDOL-induced LDLR degradation through 
direct binding of PT to the LDLR ubiquitination site is also a possible 
mechanism by which PT could stabilize LDLR. 
Furthermore, the PT-induced reduction in PCSK9 and stabilization of 
LDLR led us to establish the hypothesis that PT application in hyper-
cholesterolemia overcomes statin resistance and intolerance. Indeed, 
our results demonstrated that in the statin-treated DLPS group, PT 
completely inhibited PCSK9 expression and stabilized LDLR to a greater 
degree than in the DLPS treated group. However, PCSK9 mRNA 
expression was clearly suppressed in the absence of changes in SREBP2 
and HNF1α expression, demonstrating that the reduction in PCSK9 
expression is likely mediated by a different mechanism than that of lipid 
depletion. In this regard, we believed that in the statin-treated condi-
tions, PT regulated PCSK9 epigenetically. 
Controlling gene expression by changing histone acetylation patterns 
of a gene is a representative epigenetic mechanism and is regulated by 
histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
[61]. There are now several known HAT inhibitors (HATi) derived from 
nutrients, such as EGCG [62], anacardic acid [63], curcumin [64], and 
tannic acid [65], with safety profiles that suggest HATs are a plausible 
target for preventive or therapeutic agents [66,67]. Although there was 
a report demonstrating the potential of PT as a novel HDAC inhibitor 
(HDACi) [68], to the best of our knowledge, no studies have suggested 
its potential as a HATi. In this present study, we found that PT func-
tioned as a novel HATi against p300. By extension, to address the mode 
of action of PT as a HATi, we simulated a possible p300-PT docking 
model, which revealed that PT interacts with the HAT domain of p300. 
The autoacetylation of the p300 HAT domain, which is dependent on the 
binding of the domain to acetyl-CoA, is important for its catalytic ac-
tivity [69]. For this reason, in the evaluation of small molecules to 
discover p300 inhibitors, the binding of small molecules to the HAT 
domain serves as a critical indicator [70,71]. Taken together, our results 
suggest that PT competitively binds with acetyl-CoA to the p300 HAT 
domain, which functions as a catalytic pocket, and negatively regulates 
the transcription of genes by interacting directly with histone tails to 
obstruct the autoinhibitory function of p300. This indicates a potential 
application for a new class of PT nutraceuticals with p300 inhibitory 
activity. Indeed, p300 activity was inhibited with a specific inhibitor, 
C-646, and genetically by using siRNA against p300, both of which were 
able to effectively reduce the statin-induced increase in PCSK9 expres-
sion. To date, no study has shown that p300 is directly implicated in 
transcriptionally regulating PCSK9; however, several studies have 
indicated the possibility of epigenetic regulation of PCSK9 expression. In 
2013, Dong XC et al. revealed that Sirtuin 6 (Sirt6), an NAD 
(+)-dependent histone deacetylase, was recruited to the PCSK9 prox-
imal promoter region with the forkhead transcription factor (FOXO3), 
where it causes deacetylation of histone H3K9 and H3K56 to suppress 
PCSK9 and stabilize LDLR expression [27]. Recently, targeting PCSK9 
with three microRNAs (miRNAs), miR-191, miR-222, and miR-224, was 
shown to decrease its expression in HepG2 cells [72]. These results 
support our hypothesis that PCSK9 mRNA expression is epigenetically 
regulated. Based on these previous reports, to directly confirm the 
involvement of p300 in PCSK9 regulation, a ChIP assay was performed 
with the PCSK9 promoter region (–339 to –278 bp), which is the site at 
which p300 is expected to be recruited. Surprisingly, p300 was found to 
occupy the promoter region following simvastatin treatment, and this 
interaction was completely obstructed by PT. In general, p300 occu-
pancy correlates with transcriptional activation of a gene [73]. In 
addition, some reports demonstrated that HNF1α, which is responsible 
for PCSK9 transcription, forms a coactivator complex with p300/CBP 
[74,75]. Thus, it is possible that p300 was co-recruited with HNF1α on 
the PCSK9 promoter region and enhanced the transcriptional activity of 
the gene. Furthermore, hyperacetylation on histone tails by p300 facil-
itates loosening the chromatin structure to thereby accelerate gene 
transcription [76]. Although we did not fully identify the mechanism of 
regulation of PCSK9 with statin alone or the statin-PT combination in 
detail, our study is the first to demonstrate a plausible mechanism by 
which PT induces statin resistance and tolerance through reducing 
PCSK9 expression based on an epigenetic mechanism implicating p300. 
Finally, our hypothesis was firmly supported by animal experiments 
designed with minimal modification based on previous studies as 
mentioned in the Materials and Methods section [36,34,35]. To our 
knowledge, there have been few attempts to use a phytochemical to 
alleviate statin side effects in an animal model. As expected, after HFD 
feeding for 16 weeks, the total-C and LDL-C levels in the blood of mice 
were significantly reduced in the simvastatin-administered group. These 
results were consistent with previous studies [34,77]. Interestingly, the 
simvastatin-PT combination more effectively reduced the LDL-C level 
compared to simvastatin single treatment in HFD-fed mice. As shown in 
Fig. 6D, this phenomenon was presumed to be caused by inhibition of 
the statin-elicited LDLR degradation in the livers of HFD-fed mice 
following PT administration. However, despite numerous attempts, we 
unfortunately failed to detect the matured PCSK9 expression in mouse 
livers. PCSK9 is mainly synthesized, undergoes autocatalytic cleavage 
(matured form), and is secreted to the blood as a molecular chaperone to 
direct LDLR degradation [78]. We suspect that the major cause of our 
failure in this respect was that we overlooked the rapid movement of 
matured PCKS9 to the blood after its posttranslational modification in 
the liver. 
In summary, the present study demonstrated that PT is a potential 
p300 inhibitor that represses statin-induced PCSK9 expression and 
further stabilizes LDLR expression through its p300-inhibitory activity 
(Fig. 7). This indicates that statin resistance and tolerance could be 
ameliorated by PT treatment. Although the importance of phytochemi-
cals, including PT, is increasing daily, several issues regarding their 
practical application remain to be addressed. Moreover, it is necessary to 
note the limitation of our study. First, although, it is clear that the effects 
of DLPS-only or the DLPS-statin combination are significantly reduced 
by PT, the mechanism of action appears to be completely different 
depending on the cellular environment. We predict that there are 
complex pharmacological mechanisms beyond our current under-
standing of this issue. It is therefore important to understand this before 
proceeding to clinical applications. Second, as mentioned in the pre-
ceding paragraph, we failed to detect the expression of the PCSK9 
matured form to examine its direct role in LDLR degradation. In addi-
tion, we did not measure the PCSK9 level in the blood due to the limited 
volume available in the present study. Based on the LDLR stabilization 
and LDL-C reduction following the statin-PT combined treatment 
compared with those of the statin single treatment group, it could be 
inferred that statin-induced PCSK9 might be suppressed by PT. Third, we 
have not been able to directly compare the efficacy of evolocumab with 
PT owing to lack of availability based on patent issues. 
Despite the above limitations, our study strongly suggests a benefi-
cial effect of PT in overcoming statin resistance and tolerance in vivo. 
Furthermore, this study provides the first evidence of the underlying 
molecular mechanism of these effects from an epigenetic perspective. 
However, considering the significance of the aforementioned issues, 
further in-depth studies should be performed to understand the mech-
anism of action of PT in more detail and the complex network of genes 
involved to provide a new therapeutic strategy for 
hypercholesterolemia. 
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